Business Description
Arena Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US0400476075
Share Class Description:
FRA:RN3N: Ordinary SharesDescription
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 13.36 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | 27.59 | |||||
| Beneish M-Score | -1.42 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -86.2 | |||||
| 3-Year EBITDA Growth Rate | -53.8 | |||||
| 3-Year EPS without NRI Growth Rate | -155.2 | |||||
| 3-Year FCF Growth Rate | -45 | |||||
| 3-Year Book Growth Rate | -3.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | 67.34 | |||||
| 12-1 Month Momentum % | 28.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.59 | |||||
| Quick Ratio | 8.59 | |||||
| Cash Ratio | 8.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.6 | |||||
| Shareholder Yield % | 0.07 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1026468.52 | |||||
| Net Margin % | -1141542.59 | |||||
| FCF Margin % | -932637.99 | |||||
| ROE % | -66.84 | |||||
| ROA % | -59.91 | |||||
| ROIC % | -449.16 | |||||
| ROC (Joel Greenblatt) % | -3064.44 | |||||
| ROCE % | -64.57 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 99990 | |||||
| PB Ratio | 9.14 | |||||
| Price-to-Tangible-Book | 9.14 | |||||
| EV-to-EBIT | -9.02 | |||||
| EV-to-EBITDA | -9.08 | |||||
| EV-to-Revenue | 104741.93 | |||||
| EV-to-FCF | -10.81 | |||||
| Price-to-Median-PS-Value | 3016.67 | |||||
| Price-to-Net-Current-Asset-Value | 13.45 | |||||
| Price-to-Net-Cash | 14.03 | |||||
| Earnings Yield (Greenblatt) % | -11.09 | |||||
| FCF Yield % | -8.59 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arena Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.048 | ||
| EPS (TTM) (€) | -8.632 | ||
| Beta | 0 | ||
| Volatility % | 82.16 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 1.214286 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | 28.68 | ||
| 52-Week Range (€) | 38.6 - 90.5 | ||
| Shares Outstanding (Mil) | 61.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arena Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arena Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Arena Pharmaceuticals Inc Frequently Asked Questions
What is Arena Pharmaceuticals Inc(FRA:RN3N)'s stock price today?
The current price of FRA:RN3N is €90.50. The 52 week high of FRA:RN3N is €90.50 and 52 week low is €38.60.
When is next earnings date of Arena Pharmaceuticals Inc(FRA:RN3N)?
The next earnings date of Arena Pharmaceuticals Inc(FRA:RN3N) is .
Does Arena Pharmaceuticals Inc(FRA:RN3N) pay dividends? If so, how much?
Arena Pharmaceuticals Inc(FRA:RN3N) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers